Abstract
Background:
Radiotherapy plays an important role in the treatment of lung cancer. However, radiation-related deaths from cardiovascular disease (CVD) are a concern in these patients, and few studies have examined CVD-related death associated with lung cancer. We aimed to evaluate the risk of CVD-related death after radiotherapy in patients with lung and bronchus cancer.
Methods:
Data were extracted from the surveillance, epidemiology, and end results database. Propensity score matching (PSM) was applied to reduce possible bias between patients who received radiotherapy and those who did not. The Kaplan–Meier method was used to estimate cardiovascular-specific survival (CVSS), and the log-rank test was used to compare CVSS between the radiotherapy and no radiotherapy groups. Cox proportional hazards regression analysis was performed to estimate the hazard ratio (HR) of CVD-related death.
Results:
A total of 225,570 patients with lung and bronchus cancer were included, and 201,282 patients remained after PSM. Radiotherapy was identified as an independent risk factor for CVSS among patients with lung and bronchus cancer before PSM (HR: 1.18, P < 0.001) and after PSM (HR: 1.18, P < 0.001). Patients treated with radiotherapy had a significantly worse CVSS than those who did not receive radiotherapy before PSM (25-year CVSS: 49.9 vs. 56.4%, P = 0.002) and after PSM (25-year CVSS: 48.4 vs. 56.7%, P < 0.001). Radiotherapy was associated with more deaths from heart disease before PSM (81.9 vs. 77.2%, P < 0.001) and after PSM (83.0 vs. 78.7%, P < 0.001).
Conclusion:
Radiotherapy is associated with an increased risk of CVD-related death, especially death from heart disease, in patients with lung and bronchus cancer. More efforts are needed to monitor cardiovascular health after radiotherapy.
1. Introduction
Cancer-related mortality is the most common cause of death in lung cancer patients (). Lung cancer patients are usually treated with a combination of surgery, chemotherapy, and radiation (). This high-intensity treatment strategy may increase morbidity and mortality associated with cardiovascular diseases (CVDs). However, few studies have examined CVD-related death associated with lung cancer.
Increased radiation-related cardiotoxicity has been observed in some patients with solid tumors during long-term follow-up, with an incubation period of more than 10 years (, ). This increased risk of CVD begins within the first 5 years after radiotherapy and increases over time, lasting more than 20 years (, ). As a result, radiation strategies are constantly updated, and modern radiation techniques have been improved to reduce the morbidity and mortality of CVD (, ). However, CVD remains the second leading cause of death in patients with lung cancer (–).
Current studies are limited by small sample sizes, inconsistent endpoints, and variable baseline cardiac risk assessments (, ). Therefore, given the improved prognosis of lung cancer and clinically significant cardiac events after radiotherapy, there is an urgent need to improve cardiac risk assessment, use valid cardiac endpoints, identify predictors, and minimize risk-reduction strategies through optimized radiotherapy. The aim of this study was to evaluate the risk of CVD-related death after radiotherapy in patients with lung and bronchus cancer.
2. Materials and methods
2.1. Patient selection
This retrospective study extracted data from the surveillance, epidemiology, and end results (SEER) database,1 which covers approximately 28% of the USA population. The cause of death was classified using the international classification of diseases-9 code, and CVD was coded as diseases of the heart, hypertension, cerebrovascular disease, atherosclerosis, aortic aneurysm/dissection, and other diseases of the arteries, arterioles, or capillaries. All procedures involving human participants were ethically conducted according to national research standards committees and the 1975 declaration of Helsinki or similar ethical standards. This study did not require ethical approval.
Lung and bronchus cancer cases diagnosed as first primary malignant tumors between 1 January 1985 and 31 December, 2014 were collected. We excluded patients with a survival time of less than 2 months, unknown race, or unknown stage.
2.2. Statistical analysis
Propensity score matching (PSM) was applied to reduce possible bias from non-randomized treatment assignments. We matched patients based on sex, age at diagnosis, and year of diagnosis. The Chi-square test was used to compare the baseline distribution of patients with lung and bronchus cancer in the radiotherapy and no radiotherapy groups. Univariate and multivariate Cox proportional regression analyses were performed to identify independent risk factors for cardiovascular-specific survival (CVSS). The Kaplan–Meier method was used to analyze CVSS, and the log-rank test was used to compare survival between the radiotherapy and no radiotherapy cohorts.
3. Results
3.1. Patient characteristics before and after PSM
A total of 225,570 patients with lung and bronchus cancer were extracted from the SEER database, of whom 11,871 died of CVD. Detailed information on the patient characteristics is presented in Table 1. A total of 112,621 patients received radiotherapy and were included in the radiotherapy group, and 112,949 patients did not receive radiotherapy and were included in the no radiotherapy group. After PSM, 201,282 patients with lung and bronchus cancer were included: 100,641 patients in the radiotherapy group and 100,641 patients in the no radiotherapy group. Among these patients, 10,795 died of CVD. Detailed information on patient characteristics after PSM is shown in Table 2.
TABLE 1
| Characteristic | No radiotherapy | Radiotherapy | Overall | |||
| Alive and other deaths | CVD deaths | Alive and other deaths | CVD deaths | Alive and other deaths | CVD deaths | |
| (N = 105,585) | (N = 7,364) | (N = 108,114) | (N = 4,507) | (N = 213,699) | (N = 11,871) | |
| Race | ||||||
| White | 86,272 (81.7%) | 6,043 (82.1%) | 87,377 (80.8%) | 3,582 (79.5%) | 173,649 (81.3%) | 9,625 (81.1%) |
| Black | 10,950 (10.4%) | 871 (11.8%) | 12,748 (11.8%) | 618 (13.7%) | 23,698 (11.1%) | 1,489 (12.5%) |
| Other | 8,363 (7.9%) | 450 (6.1%) | 7,989 (7.4%) | 307 (6.8%) | 16,352 (7.7%) | 757 (6.4%) |
| Sex | ||||||
| Female | 50,181 (47.5%) | 3,233 (43.9%) | 46,260 (42.8%) | 1,689 (37.5%) | 96,441 (45.1%) | 4,922 (41.5%) |
| Male | 55,404 (52.5%) | 4,131 (56.1%) | 61,854 (57.2%) | 2,818 (62.5%) | 117,258 (54.9%) | 6,949 (58.5%) |
| Age at diagnosis | ||||||
| 0–39 | 1,363 (1.3%) | 16 (0.2%) | 1,219 (1.1%) | 16 (0.4%) | 2,582 (1.2%) | 32 (0.3%) |
| 40–59 | 22,677 (21.5%) | 801 (10.9%) | 31,104 (28.8%) | 772 (17.1%) | 53,781 (25.2%) | 1,573 (13.3%) |
| 60–79 | 65,520 (62.1%) | 4,994 (67.8%) | 65,686 (60.8%) | 2,995 (66.5%) | 131,206 (61.4%) | 7,989 (67.3%) |
| >80 | 16,025 (15.2%) | 1,553 (21.1%) | 10,105 (9.3%) | 724 (16.1%) | 26,130 (12.2%) | 2,277 (19.2%) |
| Year at diagnosis | ||||||
| 1985–1994 | 22,663 (21.5%) | 2,432 (33.0%) | 29,141 (27.0%) | 1,425 (31.6%) | 51,804 (24.2%) | 3,857 (32.5%) |
| 1995–2004 | 38,469 (36.4%) | 3,015 (40.9%) | 40,338 (37.3%) | 1,819 (40.4%) | 78,807 (36.9%) | 4,834 (40.7%) |
| 2005–2014 | 44,453 (42.1%) | 1,917 (26.0%) | 38,635 (35.7%) | 1,263 (28.0%) | 83,088 (38.9%) | 3,180 (26.8%) |
| Stage | ||||||
| Localized | 27,402 (26.0%) | 3,648 (49.5%) | 9,754 (9.0%) | 998 (22.1%) | 37,156 (17.4%) | 4,646 (39.1%) |
| Regional | 25,876 (24.5%) | 1,998 (27.1%) | 36,418 (33.7%) | 2,147 (47.6%) | 62,294 (29.2%) | 4,145 (34.9%) |
| Distant | 52,307 (49.5%) | 1,718 (23.3%) | 61,942 (57.3%) | 1,362 (30.2%) | 114,249 (53.5%) | 3,080 (25.9%) |
| Chemotherapy | ||||||
| Yes | 41,669 (39.5%) | 1,131 (15.4%) | 64,121 (59.3%) | 2,023 (44.9%) | 105,790 (49.5%) | 3,154 (26.6%) |
| No | 63,916 (60.5%) | 6,233 (84.6%) | 43,993 (40.7%) | 2,484 (55.1%) | 107,909 (50.5%) | 8,717 (73.4%) |
Baseline characteristics before PSM.
PSM, propensity score matching; CVD, cardiovascular disease.
TABLE 2
| Characteristic | No radiotherapy | Radiotherapy | Overall | |||
| Alive and other deaths | CVD deaths | Alive and other deaths | CVD deaths | Alive and other deaths | CVD deaths | |
| (N = 94,000) | (N = 6,641) | (N = 96,487) | (N = 4,154) | (N = 190,487) | (N = 10,795) | |
| Race | ||||||
| White | 76,854 (81.8%) | 5,444 (82.0%) | 79,481 (82.4%) | 3,345 (80.5%) | 156,335 (82.1%) | 8,789 (81.4%) |
| Black | 10,045 (10.7%) | 798 (12.0%) | 10,343 (10.7%) | 543 (13.1%) | 20,388 (10.7%) | 1,341 (12.4%) |
| Other | 7,101 (7.6%) | 399 (6.0%) | 6,663 (6.9%) | 266 (6.4%) | 13,764 (7.2%) | 665 (6.2%) |
| Sex | ||||||
| Female | 42,199 (44.9%) | 2,727 (41.1%) | 43,647 (45.2%) | 1,627 (39.2%) | 85,846 (45.1%) | 4,354 (40.3%) |
| Male | 51,801 (55.1%) | 3,914 (58.9%) | 52,840 (54.8%) | 2,527 (60.8%) | 104,641 (54.9%) | 6,441 (59.7%) |
| Age at diagnosis | ||||||
| 0–39 | 1,131 (1.2%) | 14 (0.2%) | 1,172 (1.2%) | 14 (0.3%) | 2,303 (1.2%) | 28 (0.3%) |
| 40–59 | 22,677 (24.1%) | 801 (12.1%) | 22,826 (23.7%) | 579 (13.9%) | 45,503 (23.9%) | 1,380 (12.8%) |
| 60–79 | 60,401 (64.3%) | 4,790 (72.1%) | 62,384 (64.7%) | 2,837 (68.3%) | 122,785 (64.5%) | 7,627 (70.7%) |
| >80 | 9,791 (10.4%) | 1,036 (15.6%) | 10,105 (10.5%) | 724 (17.4%) | 19,896 (10.4%) | 1,760 (16.3%) |
| Year at diagnosis | ||||||
| 1985–1994 | 22,243 (23.7%) | 2,385 (35.9%) | 23,397 (24.2%) | 1,201 (28.9%) | 45,640 (24.0%) | 3,586 (33.2%) |
| 1995–2004 | 35,295 (37.5%) | 2,738 (41.2%) | 36,868 (38.2%) | 1,723 (41.5%) | 72,163 (37.9%) | 4,461 (41.3%) |
| 2005–2014 | 36,462 (38.8%) | 1,518 (22.9%) | 36,222 (37.5%) | 1,230 (29.6%) | 72,684 (38.2%) | 2,748 (25.5%) |
| Stage | ||||||
| Localized | 24,199 (25.7%) | 3,295 (49.6%) | 9,146 (9.5%) | 946 (22.8%) | 33,345 (17.5%) | 4,241 (39.3%) |
| Regional | 23,073 (24.5%) | 1,824 (27.5%) | 32,323 (33.5%) | 1,939 (46.7%) | 55,396 (29.1%) | 3,763 (34.9%) |
| Distant | 46,728 (49.7%) | 1,522 (22.9%) | 55,018 (57.0%) | 1,269 (30.5%) | 101,746 (53.4%) | 2,791 (25.9%) |
| Chemotherapy | ||||||
| Yes | 38,265 (40.7%) | 1,053 (15.9%) | 56,860 (58.9%) | 1,843 (44.4%) | 95,125 (49.9%) | 2,896 (26.8%) |
| No | 55,735 (59.3%) | 5,588 (84.1%) | 39,627 (41.1%) | 2,311 (55.6%) | 95,362 (50.1%) | 7,899 (73.2%) |
Baseline characteristics after PSM.
PSM, propensity score matching; CVD, cardiovascular disease.
3.2. Association between radiotherapy and CVSS
In univariate and multivariable Cox proportional hazards regression analyses before PSM, radiotherapy was an independent risk factor for CVSS among patients with lung and bronchus cancer [hazard ratio (HR): 1.18, 95% confidence interval (CI): 1.13–1.23, P < 0.001] after adjusting for race, sex, age at diagnosis, year of diagnosis, stage, and administration of chemotherapy (Table 3). After PSM, radiotherapy was still an independent risk factor for CVSS among patients with lung and bronchus cancer (HR: 1.18, 95% CI: 1.13–1.23, P < 0.001) (Table 4).
TABLE 3
| Characteristic | Univariable analysis | Multivariable analysis | ||||
| HR | CI | P | HR | CI | P | |
| Race | ||||||
| White | 1 | 1 | ||||
| Black | 1.31 | 1.24–1.38 | < 0.001 | 1.51 | 1.43–1.60 | < 0.001 |
| Other | 0.83 | 0.77–0.90 | < 0.001 | 0.81 | 0.76–0.88 | < 0.001 |
| Sex | ||||||
| Female | 1 | 1 | ||||
| Male | 1.48 | 1.42–1.53 | < 0.001 | 1.5 | 1.44–1.55 | < 0.001 |
| Age at diagnosis | ||||||
| 0–39 | 1 | 1 | ||||
| 40–59 | 4.83 | 3.40–6.85 | < 0.001 | 4.87 | 3.43–6.92 | < 0.001 |
| 60–79 | 13.00 | 9.18–18.41 | < 0.001 | 13.40 | 9.46–18.97 | < 0.001 |
| >80 | 27.78 | 19.58–39.43 | < 0.001 | 30.16 | 21.25–42.82 | < 0.001 |
| Year at diagnosis | ||||||
| 1985–1994 | 1 | 1 | ||||
| 1995–2004 | 0.82 | 0.79–0.86 | < 0.001 | 0.85 | 0.81–0.88 | < 0.001 |
| 2005–2014 | 0.60 | 0.57–0.63 | < 0.001 | 0.61 | 0.58–0.65 | < 0.001 |
| Stage | ||||||
| Localized | 1 | 1 | ||||
| Regional | 1.02 | 0.98–1.06 | 0.365 | 1.14 | 1.09–1.20 | < 0.001 |
| Distant | 1.07 | 1.01–1.12 | 0.012 | 1.41 | 1.33–1.48 | < 0.001 |
| Chemotherapy | ||||||
| No | 1 | 1 | ||||
| Yes | 0.60 | 0.58–0.63 | < 0.001 | 0.66 | 0.63–0.7 | < 0.001 |
| Radiotherapy | ||||||
| No | 1 | 1 | ||||
| Yes | 1.06 | 1.02–1.10 | 0.002 | 1.18 | 1.13–1.23 | < 0.001 |
Cox proportional hazards regression analyses for CVSS before PSM.
CVSS, cardiovascular-specific survival; PSM, propensity score matching; HR, hazard ratio; CI, confidence interval.
TABLE 4
| Characteristic | Univariable analysis | Multivariable analysis | ||||
| HR | CI | P | HR | CI | P | |
| Race | ||||||
| White | 1 | 1 | ||||
| Black | 1.32 | 1.25–1.40 | < 0.001 | 1.53 | 1.44–1.62 | < 0.001 |
| Other | 0.85 | 0.78–0.91 | < 0.001 | 0.82 | 0.75–0.88 | < 0.001 |
| Sex | ||||||
| Female | 1 | 1 | ||||
| Male | 1.53 | 1.47–1.59 | < 0.001 | 1.51 | 1.45–1.57 | < 0.001 |
| Age at diagnosis | ||||||
| 0–39 | 1 | 1 | ||||
| 40–59 | 4.75 | 3.26–6.90 | < 0.001 | 4.98 | 3.43–7.25 | < 0.001 |
| 60–79 | 13.31 | 9.17–19.30 | < 0.001 | 13.92 | 9.60–20.19 | < 0.001 |
| >80 | 28.56 | 19.64–41.54 | < 0.001 | 30.42 | 20.91–44.25 | < 0.001 |
| Year at diagnosis | ||||||
| 1985–1994 | 1 | 1 | ||||
| 1995–2004 | 0.81 | 0.77–0.84 | < 0.001 | 0.84 | 0.81–0.88 | < 0.001 |
| 2005–2014 | 0.58 | 0.55–0.61 | < 0.001 | 0.61 | 0.58–0.64 | < 0.001 |
| Stage | ||||||
| Localized | 1 | 1 | ||||
| Regional | 1.04 | 1.00–1.09 | 0.060 | 1.15 | 1.10–1.21 | < 0.001 |
| Distant | 1.09 | 1.03–1.15 | 0.001 | 1.42 | 1.34–1.50 | < 0.001 |
| Chemotherapy | ||||||
| No | 1 | 1 | ||||
| Yes | 0.62 | 0.59–0.64 | < 0.001 | 0.66 | 0.63–0.70 | < 0.001 |
| Radiotherapy | ||||||
| No | 1 | 1 | ||||
| Yes | 1.12 | 1.08–1.17 | < 0.001 | 1.18 | 1.13–1.23 | < 0.001 |
Cox proportional hazards regression analyses for CVSS after PSM.
CVSS, cardiovascular-specific survival; PSM, propensity score matching; HR, hazard ratio; CI, confidence interval.
Furthermore, univariate Cox proportional hazards regression analyses were conducted for subgroup analyses. The forest plots summarize the HRs and 95% CIs comparing radiotherapy with no radiotherapy before PSM (Figure 1) and after PSM (Figure 2). Radiotherapy was associated with worse CVSS in most subgroups, except in patients aged > 80 years (before PSM, HR: 0.91, 95% CI: 0.83–0.99, P = 0.037; after PSM, HR: 0.85, 95% CI: 0.77–0.94, P = 0.001) and those with distant stage (before PSM, HR: 0.67, 95% CI: 0.62–0.72, P < 0.001; after PSM, HR: 0.71, 95% CI: 0.66–0.77, P < 0.001).
FIGURE 1
FIGURE 2
3.3. CVSS comparison in patients who did and did not receive radiotherapy
The Kaplan–Meier method was used to estimate the long-term CVSS in patients with lung and bronchus cancer (Figure 3). Patients receiving radiotherapy had significantly worse CVSS than those not receiving radiotherapy (before PSM, 25-year CVSS: 49.9 vs. 56.4%, P = 0.002; after PSM, 25-year CVSS: 48.4 vs. 56.7%, P < 0.001). Subgroup analyses showed similar results (Supplementary Figures 1–12); patients who underwent radiotherapy had significantly worse CVSS in most subgroups, except for patients > 80 years (before PSM, 20-year CVSS: 20.0 vs. 13.4%, P = 0.037; after PSM, 20-year CVSS: 20.0 vs. 13.0%, P = 0.001) and those with distant metastasis (before PSM, 29-year CVSS: 57.4 vs. 51.8%, P < 0.001; after PSM, 29-year CVSS: 54.4 vs. 52.8%, P < 0.001).
FIGURE 3
3.4. Different causes of CVD-related death
We used the Chi-square test to compare different causes of CVD-related death in patients with lung and bronchus cancer who did and did not receive radiotherapy (Figure 4). The results demonstrated that deaths from heart disease were more common in the radiotherapy group than in the no radiotherapy group (before PSM: 81.9 vs. 77.2%, P < 0.001; after PSM: 83.0 vs. 78.7%, P < 0.001). However, fewer patients who underwent radiotherapy died of other types of CVD before and after PSM.
FIGURE 4
4. Discussion
In this large population-based study, there was a significant association between radiotherapy and CVD-related death, and radiotherapy increased the risk of CVD-related death in patients with lung and bronchus cancer. Most stratified analyses found that radiotherapy was associated with a worse CVSS, and radiotherapy was associated with an increased risk of death from heart disease. We then performed PSM to reduce possible bias from non-randomized treatment assignments, and similar results were found after PSM.
Cardiovascular disease is the leading cause of non-cancer death among patients with various solid tumors (, ) and the highest cause of non-tumor death in lung cancer, even surpassing tumors as the leading cause of death in patients with early stage disease (–). Radiotherapy might play an important role in promoting CVD by increasing cardiotoxicity (). Time-dependent cardiotoxicity usually appears in the second year after radiotherapy, with a typical incubation period of more than 10 years, and the incidence increases with the cardiac dose (, ). However, previous studies may have overlooked the risk of CVD deaths in lung and bronchus cancer patients who underwent radiotherapy because of small sample sizes and short time spans. To address these limitations, this study enrolled more than 200,000 patients with lung and bronchus cancer between 1985 and 2014, of whom nearly 50% underwent radiotherapy. The longer time span allowed for the inclusion of more patients, which facilitated a comprehensive analysis of the risk of CVD-related death in patients with lung and bronchus cancer. Consistent with the results of previous studies, we observed that radiotherapy increased the risk of CVD-related death in patients with lung and bronchus cancer. Furthermore, the application of PSM reduced possible bias and confounding variables, and a more accurate comparison yielded the same results, which proves the credibility of this study.
The underlying mechanism of radiation-induced CVD may be related to early microvascular changes and late macrovascular atherosclerosis induced by direct cardiac irradiation and radiotherapy (, ). Typical characteristics include fibrosis and calcification of the aortic root and wall, stenosis of the coronary orifice, myocardial atrophy, and extensive pericardial adhesion ().
Radiation strategies have changed over the past few decades, which might influence the risk of CVD-related death in cancer patients (, ). Modern radiation techniques and doses have been modified to reduce the incidence and mortality of CVD (, ). Therefore, it is believed that patients with lung and bronchus cancer who were diagnosed more recently will have a decreased risk of CVD-related death following radiotherapy. However, our results demonstrated that radiotherapy was associated with a worse CVSS after PSM in patients treated between 2005 and 2014. In line with the results of previous studies, we showed that radiotherapy increased the risk of CVD-related death in patients with lung cancer who were diagnosed more recently (, , ). Hence, cardiovascular health should be monitored for a long time after radiotherapy for lung and bronchus cancer. The European Society for Medical Oncology also recommends screening before anticancer therapy, such as baseline cardiac biomarker measurement, electrocardiography, and left ventricular ejection fraction tests ().
Aging has profound effects on the structure and function of blood vessels (, ). As people age, there are usually changes in the cardiovascular system that can lead to CVD (). Therefore, advanced age might contribute to increased morbidity and mortality associated with CVD. Radiotherapy may further increase the burden on the heart and blood vessels. However, our results suggested that radiotherapy was associated with better CVSS among lung and bronchus cancer patients over 80 years of age, whereas it was associated with worse CVSS in younger patients. Previous studies have also demonstrated that older patients with lung cancer have better CVSS after radiotherapy (, ). One possible explanation for this phenomenon is that older patients are more likely to forgo radiotherapy in consideration of adverse events, which might increase the number of CVD deaths in patients without radiotherapy. Another explanation could be a loss to follow-up or an incorrect cause of death. Previous studies have suggested that a subset of cancer patients die without disease progression or distant metastasis, which cannot be attributed to death from cancer (). Nearly one-third of the causes of death may be incorrect, and half are determined from autopsy reports (, ). In addition, advanced age is often accompanied by preexisting CVD (, ), which is associated with an increased risk of CVD-related death. Therefore, the results regarding the effect of radiotherapy on CVD-related death in older patients should be carefully interpreted.
After stratifying by stage at diagnosis, we observed that radiotherapy improved CVSS in patients with distant metastasis, which is consistent with the results of previous studies (, ). Tumors are the leading cause of death in cancer patients with distant metastasis (). Because radiation-related cardiovascular death often occurs 10 years after radiotherapy, the short survival time in patients with distant metastasis might misjudge the effect of radiotherapy on CVD-related death (, , ). In addition, treatment is complicated in patients with advanced cancer and depends on the metastatic organs, extent of invasion, and genetic or protein changes (, ). Targeted therapy and immunotherapy may also affect the survival outcomes of patients with advanced cancer, but information on treatment could not be obtained from the SEER database. Because of the heterogeneity of advanced cancer and the disunity of the treatment strategy, more studies are needed to determine the true effect of radiotherapy on lung and bronchus cancer patients with distant metastasis.
This study had some limitations. First, previous studies have demonstrated that cardiotoxicity in lung cancer patients receiving radiotherapy was independently associated with cardiac dose, including total cardiac dose, average cardiac dose, fractionation schedule, and percentage of heart-received radiation (). In order to reduce the occurrence of cardiac adverse events in thoracic neoplasms, the national comprehensive cancer network clinical practice guidelines in oncology for esophageal and esophagogastric junction cancer set the average cardiac dose at 30 Gy. Still, the latest study suggests that an average cardiac dose of less than 15 Gy can reduce severe cardiac events (). Hence, radiation dose was critical to CVD-related death. But detailed information on radiation techniques and doses, which can influence the incidence of CVD-related death, was not provided in the SEER database. And this limitation restricted the further exploration of the association between radiation dose and risk of CVD-related death, which need prospective studies to verify the results. Second, the SEER database did not provide information on comorbidities and preexisting CVD, which are independent risk factors for CVD-related death. Third, this was a retrospective study with possible biases and confounding variables. Although PSM was performed, prospective randomized controlled studies are required to validate our results.
5. Conclusion
This study suggests that radiotherapy is associated with worse CVSS in patients with lung and bronchus cancer, which emphasizes the importance of long-term monitoring of cardiovascular health in patients after radiotherapy.
Statements
Data availability statement
The original contributions presented in this study are included in the article/Supplementary material, further inquiries can be directed to ZY.
Author contributions
MZ designed the study and revised the manuscript. ZY, YZ, YuW, and MZ collected and checked the data. YG, YW, XL, SR, NG, and JQ analyzed the data. ZY drafted the manuscript. All authors contributed to the article and approved the submitted version.
Funding
This work was supported by grants from the Capital Research Funds for Medical Development (2020-3-6081).
Acknowledgments
We would like to express their gratitude to the participants of this work.
Conflict of interest
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
Supplementary material
The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fcvm.2022.1068957/full#supplementary-material
Footnotes
References
1.
BartaJAPowellCAWisniveskyJP. Global epidemiology of lung cancer.Ann Glob Health. (2019) 85:8. 10.5334/aogh.2419
2.
WirsdörferFde LeveSJendrossekV. Combining radiotherapy and immunotherapy in lung cancer: can we expect limitations due to altered normal tissue toxicity?Int J Mol Sci. (2018) 20:24. 10.3390/ijms20010024
3.
BohdanMKowalczysAMickiewiczAGruchalaMLewickaE. Cancer therapy-related cardiovascular complications in clinical practice: current perspectives.J Clin Med. (2021) 10:1647. 10.3390/jcm10081647
4.
HerrmannJ. Adverse cardiac effects of cancer therapies: cardiotoxicity and arrhythmia.Nat Rev Cardiol. (2020) 17:474–502. 10.1038/s41569-020-0348-1
5.
PirothMDBaumannRBudachWDunstJFeyerPFietkauRet alHeart toxicity from breast cancer radiotherapy : current findings, assessment, and prevention.Strahlenther Onkol. (2019) 195:1–12. 10.1007/s00066-018-1378-z
6.
DarbySCMcGalePTaylorCWPetoR. Long-term mortality from heart disease and lung cancer after radiotherapy for early breast cancer: prospective cohort study of about 300,000 women in US SEER cancer registries.Lancet Oncol. (2005) 6:557–65. 10.1016/S1470-2045(05)70251-5
7.
RatosaIIvanetic PantarM. Cardiotoxicity of mediastinal radiotherapy.Rep Pract Oncol Radiother. (2019) 24:629–43. 10.1016/j.rpor.2019.09.002
8.
PadegimasAClasenSKyB. Cardioprotective strategies to prevent breast cancer therapy-induced cardiotoxicity.Trends Cardiovasc Med. (2020) 30:22–8. 10.1016/j.tcm.2019.01.006
9.
NagaiHKimYH. Cancer prevention from the perspective of global cancer burden patterns.J Thorac Dis. (2017) 9:448–51. 10.21037/jtd.2017.02.75
10.
NonakaMHosodaHUezonoY. Cancer treatment-related cardiovascular disease: current status and future research priorities.Biochem Pharmacol. (2021) 190:114599. 10.1016/j.bcp.2021.114599
11.
SunJYZhangZYQuQWangNZhangYMMiaoLFet alCardiovascular disease-specific mortality in 270,618 patients with non-small cell lung cancer.Int J Cardiol. (2021) 330:186–93. 10.1016/j.ijcard.2021.02.025
12.
WangKEblanMJDealAMLipnerMZagarTMWangYet alCardiac toxicity after radiotherapy for stage III non-small-cell lung cancer: pooled analysis of dose-escalation trials delivering 70 to 90 Gy.J Clin Oncol. (2017) 35:1387–94. 10.1200/JCO.2016.70.0229
13.
DessRTSunYMatuszakMMSunGSoniPDBazziLet alCardiac events after radiation therapy: combined analysis of prospective multicenter trials for locally advanced non-small-cell lung cancer.J Clin Oncol. (2017) 35:1395–402. 10.1200/JCO.2016.71.6142
14.
LiuMLiXCLuLCaoYSunRRChenSet alCardiovascular disease and its relationship with chronic kidney disease.Eur Rev Med Pharmacol Sci. (2014) 18:2918–26.
15.
StewartJManmathanGWilkinsonP. Primary prevention of cardiovascular disease: a review of contemporary guidance and literature.JRSM Cardiovasc Dis. (2017) 6:2048004016687211. 10.1177/2048004016687211
16.
Mc NamaraKAlzubaidiHJacksonJK. Cardiovascular disease as a leading cause of death: how are pharmacists getting involved?Integr Pharm Res Pract. (2019) 8:1–11. 10.2147/IPRP.S133088
17.
OlfsonMGerhardTHuangCCrystalSStroupTS. Premature mortality among adults with schizophrenia in the United States.JAMA Psychiatry. (2015) 72:1172–81. 10.1001/jamapsychiatry.2015.1737
18.
ZaorskyNGChurillaTMEglestonBLFisherSGRidgeJAHorwitzEMet alCauses of death among cancer patients.Ann Oncol. (2017) 28:400–7. 10.1093/annonc/mdw604
19.
AtkinsKMRawalBChaunzwaTLLambaNBittermanDSWilliamsCLet alCardiac radiation dose, cardiac disease, and mortality in patients with lung cancer.J Am Coll Cardiol. (2019) 73:2976–87. 10.1016/j.jacc.2019.03.500
20.
van NimwegenFASchaapveldMJanusCPKrolADPetersenEJRaemaekersJMet alCardiovascular disease after Hodgkin lymphoma treatment: 40-year disease risk.JAMA Intern Med. (2015) 175:1007–17. 10.1001/jamainternmed.2015.1180
21.
van NimwegenFASchaapveldMCutterDJJanusCPKrolADHauptmannMet alRadiation dose-response relationship for risk of coronary heart disease in survivors of Hodgkin lymphoma.J Clin Oncol. (2016) 34:235–43. 10.1200/JCO.2015.63.4444
22.
YoonDWShinDWChoJHYangJHJeongSMHanKet alIncreased risk of coronary heart disease and stroke in lung cancer survivors: a Korean nationwide study of 20,458 patients.Lung Cancer. (2019) 136:115–21. 10.1016/j.lungcan.2019.08.025
23.
DarbySCCutterDJBoermaMConstineLSFajardoLFKodamaKet alRadiation-related heart disease: current knowledge and future prospects.Int J Radiat Oncol Biol Phys. (2010) 76:656–65. 10.1016/j.ijrobp.2009.09.064
24.
BanfillKGiulianiMAznarMFranksKMcWilliamASchmittMet alCardiac toxicity of thoracic radiotherapy: existing evidence and future directions.J Thorac Oncol. (2021) 16:216–27. 10.1016/j.jtho.2020.11.002
25.
WangCHuKLuoCDengLFallKTamimiRMet alCardiovascular mortality among cancer survivors who developed breast cancer as a second primary malignancy.Br J Cancer. (2021) 125:1450–8. 10.1038/s41416-021-01549-w
26.
CuriglianoGLenihanDFradleyMGanatraSBaracABlaesAet alManagement of cardiac disease in cancer patients throughout oncological treatment: ESMO consensus recommendations.Ann Oncol. (2020) 31:171–90. 10.1016/j.annonc.2019.10.023
27.
ShahDJSachsRKWilsonDJ. Radiation-induced cancer: a modern view.Br J Radiol. (2012) 85:e1166–73. 10.1259/bjr/25026140
28.
OhIJAhnSJ. Multidisciplinary team approach for the management of patients with locally advanced non-small cell lung cancer: searching the evidence to guide the decision.Radiat Oncol J. (2017) 35:16–24. 10.3857/roj.2017.00108
29.
MingXFengYYangCWangWWangPDengJ. Radiation-induced heart disease in lung cancer radiotherapy: a dosimetric update.Medicine (Baltimore). (2016) 95:e5051. 10.1097/MD.0000000000005051
30.
LiuEGuanXWeiRJiangZLiuZWangGet alAssociation between radiotherapy and death from cardiovascular disease among patients with cancer: a large population-based cohort study.J Am Heart Assoc. (2022) 11:e023802. 10.1161/JAHA.121.023802
31.
PiccirilloFCarpenitoMVerolinoGChelloCNuscaALusiniMet alChanges of the coronary arteries and cardiac microvasculature with aging: implications for translational research and clinical practice.Mech Ageing Dev. (2019) 184:111161. 10.1016/j.mad.2019.111161
32.
EvansMASanoSWalshK. Cardiovascular disease, aging, and clonal hematopoiesis.Annu Rev Pathol. (2020) 15:419–38. 10.1146/annurev-pathmechdis-012419-032544
33.
JonesGSBaldwinDR. Recent advances in the management of lung cancer.Clin Med (Lond). (2018) 18:s41–6. 10.7861/clinmedicine.18-2-s41
34.
ZhangBLiuRRenDLiXWangYHuoHet alComparison of lobectomy and sublobar resection for stage IA elderly NSCLC patients (>/=70 Years): a population-based propensity score matching’s study.Front Oncol. (2021) 11:610638. 10.3389/fonc.2021.610638
35.
SunFFranksKMurrayLLilleyJWhellerBBanfillKet alCardiovascular mortality and morbidity following radical radiotherapy for lung cancer: is cardiovascular death under-reported?Lung Cancer. (2020) 146:1–5. 10.1016/j.lungcan.2020.05.004
36.
LagerwaardFJSenanSvan MeerbeeckJPGravelandWJ. Rotterdam oncological thoracic study G Has 3-D conformal radiotherapy (3D CRT) improved the local tumour control for stage I non-small cell lung cancer?Radiother Oncol. (2002) 63:151–7. 10.1016/s0167-8140(02)00009-9
37.
SharmaJCFletcherSVassalloMRossI. Cardiovascular disease and outcome of acute stroke: influence of pre-existing cardiac failure.Eur J Heart Fail. (2000) 2:145–50. 10.1016/s1388-9842(00)00067-2
38.
LuoYJiangYXuHLyuHZhangLYinPet alRisk of post-operative cardiovascular event in elderly patients with pre-existing cardiovascular disease who are undergoing hip fracture surgery.Int Orthop. (2021) 45:3045–53. 10.1007/s00264-021-05227-7
39.
ZhangRLiPLiQQiaoYXuTRuanPet alRadiotherapy improves the survival of patients with extensive-disease small-cell lung cancer: a propensity score matched analysis of surveillance, epidemiology, and end results database.Cancer Manag Res. (2018) 10:6525–35. 10.2147/CMAR.S174801
40.
QiJXuLSunJWangXZhaoL. Thoracic radiotherapy benefits elderly extensive-stage small cell lung cancer patients with distant metastasis.Cancer Manag Res. (2019) 11:10767–75. 10.2147/CMAR.S221225
41.
EspositoMGanesanSKangY. Emerging strategies for treating metastasis.Nat Cancer. (2021) 2:258–70. 10.1038/s43018-021-00181-0
42.
PalmaDAOlsonRHarrowSGaedeSLouieAVHaasbeekCet alStereotactic ablative radiotherapy versus standard of care palliative treatment in patients with oligometastatic cancers (SABR-COMET): a randomised, phase 2, open-label trial.Lancet. (2019) 393:2051–8. 10.1016/S0140-6736(18)32487-5
43.
BahadoerRRDijkstraEAvan EttenBMarijnenCAMPutterHKranenbargEMet alShort-course radiotherapy followed by chemotherapy before total mesorectal excision (TME) versus preoperative chemoradiotherapy, TME, and optional adjuvant chemotherapy in locally advanced rectal cancer (RAPIDO): a randomised, open-label, phase 3 trial.Lancet Oncol. (2021) 22:29–42. 10.1016/S1470-2045(20)30555-6
44.
TranNHBekaii-SaabT. Optimizing chemotherapy choice in the treatment of advanced pancreatic cancer-it is complicated.JAMA Netw Open. (2021) 4:e2134458. 10.1001/jamanetworkopen.2021.34458
45.
HannaNHRobinsonAGTeminSBakerSJr.BrahmerJREllisPMet alTherapy for stage IV non-small-cell lung cancer with driver alterations: ASCO and OH (CCO) joint guideline update.J Clin Oncol. (2021) 39:1040–91. 10.1200/JCO.20.03570
46.
PalaskasNPatelAYusufSW. Radiation and cardiovascular disease.Ann Transl Med. (2019) 7:S371. 10.21037/atm.2019.08.107
47.
WangXPalaskasNLYusufSWAbeJILopez-MatteiJBanchsJet alIncidence and onset of severe cardiac events after radiotherapy for esophageal cancer.J Thorac Oncol. (2020) 15:1682–90. 10.1016/j.jtho.2020.06.014
Summary
Keywords
lung and bronchus, cancer, radiotherapy, cardiovascular diseases, death
Citation
Yi Z, Zhang Y, Wang Y, Gao Y, Wang Y, Li X, Ru S, Guo N, Qiu J and Zhang M (2023) Association between radiotherapy and risk of death from cardiovascular diseases in lung and bronchus cancer. Front. Cardiovasc. Med. 9:1068957. doi: 10.3389/fcvm.2022.1068957
Received
13 October 2022
Accepted
28 December 2022
Published
12 January 2023
Volume
9 - 2022
Edited by
Guan Xu, Chinese Academy of Medical Sciences and Peking Union Medical College, China
Reviewed by
Chu Xianming, The Affiliated Hospital of Qingdao University, China; Michael Spartalis, National and Kapodistrian University of Athens, Greece
Updates
Copyright
© 2023 Yi, Zhang, Wang, Gao, Wang, Li, Ru, Guo, Qiu and Zhang.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Meng Zhang, mengzhangmd@126.com
This article was submitted to Cardio-Oncology, a section of the journal Frontiers in Cardiovascular Medicine
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.